Multiple Myeloma
📧 Sign up to get email alerts when something new happens for Multiple Myeloma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Loss of Expression (MATCH-Subprotocol P) [Phase 2]
Phase 2 trial update evaluating GSK2636771 in cancers with PTEN loss under the MATCH program; the study is active but not recruiting and res…
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma [Phase 1, Phase 2]
This clinical trial update reports results for Modakafusp Alfa in adults with relapsed/refractory multiple myeloma. The Phase 1/2 study has …
-
CLINICAL_TRIALS trial_result · 2025-10-20Clinical Trial Update: Isa-Pom-Dex in Elderly/Frail Subjects With RRMM [Phase 2]
A Phase 2 trial of isatuximab-pomalidomide-dexamethasone (Isa-Pom-Dex) in elderly or frail patients with relapsed/refractory multiple myelom…
-
CLINICAL_TRIALS research · 2025-10-15Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Isatuximab in Participants With RRMM [Phase 1, Phase 2]
Clinical trial update for a sub-study of belantamab mafodotin in combination with isatuximab for relapsed/refractory multiple myeloma (Phase…
-
CLINICAL_TRIALS trial_result · 2025-10-15Clinical Trial Update: Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM [Phase 1, Phase 2]
A sub-study of belantamab mafodotin in combination with feladilimab in relapsed/refractory multiple myeloma is being conducted in Phase 1/Ph…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2025-10-15Clinical Trial Update: Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma [Phase 1]
A Phase 1 trial of bendamustine hydrochloride in previously treated multiple myeloma and plasma cell leukemia has been withdrawn.
-
EMA approval · 2025-10-14EMA Authorised: Bortezomib Sun (bortezomib) — SUN Pharmaceutical Industries (Europe) B.V.
The European Medicines Agency authorised Bortezomib Sun by SUN Pharmaceutical Industries (Europe) B.V. for use in multiple myeloma.
-
CLINICAL_TRIALS research · 2025-10-14Clinical Trial Update: Family Study of Lymphoproliferative Disorders
A Mayo Clinic-led clinical trial is a family study investigating lymphoproliferative disorders, currently in the recruitment phase.
-
CLINICAL_TRIALS research · 2025-10-10Clinical Trial Update: Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. [Phase 1]
Phase 1 study evaluating Captisol-enabled melphalan pharmacokinetics in patients with multiple myeloma or AL amyloidosis undergoing autologo…
-
CLINICAL_TRIALS trial_result · 2025-10-10Clinical Trial Update: VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) [Phase 1]
This update reports termination of the first-in-human Phase 1 trial of the VOB560-MIK665 combination in relapsed/refractory hematologic mali…
-
EMA approval · 2025-10-08EMA Authorised: Tecvayli (teclistamab) — Janssen-Cilag International N.V.
The European Medicines Agency authorised Tecvayli (teclistamab) for the treatment of multiple myeloma. The approval is conditional.
-
CLINICAL_TRIALS trial_result · 2025-10-08Clinical Trial Update: A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma [Phase 1]
Phase 1 study of AMG 701 as monotherapy or with pomalidomide, with or without dexamethasone, in relapsed/refractory multiple myeloma has bee…
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: Study to Investigate Alternative Dosing Regimens of Belantamab Mafodotin in Participants With Relapsed or Refractory Multiple Myeloma [Phase 2]
Phase 2 trial evaluating alternative dosing regimens of belantamab mafodotin in relapsed or refractory multiple myeloma; the study is active…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM [Phase 2]
Phase 2 clinical trial evaluating a quadruple combination of daratumumab, carfilzomib, pomalidomide, and dexamethasone for multiple myeloma;…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) [Phase 2, Phase 3]
Clinical trial update for the Stop Ig study, assessing whether antibiotic therapy or immunoglobulin use affects infection management and dec…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) [Phase 2, Phase 3]
A Monash University trial is testing antibiotic therapy or intravenous immunoglobulin dosing to prevent infections in hematologic cancer pat…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) [Phase 2, Phase 3]
A hematology platform trial (RATIONAL-PT) is evaluating the roles of antibiotic therapy or immunoglobulin for infections in patients with he…
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients [Phase 1, Phase 2]
This clinical trial update reports HuL001 being studied in relapsed/refractory multiple myeloma in Phase 1/2, with enrollment currently by i…
-
CLINICAL_TRIALS research · 2025-10-07Clinical Trial Update: ERd Combination Treatment in Newly Diagnosed Multiple Myeloma [Phase 2]
A Phase 2 clinical trial update for an ERd (elotuzumab, lenalidomide, dexamethasone) combination as initial therapy in newly diagnosed multi…
-
CLINICAL_TRIALS trial_result · 2025-10-07Clinical Trial Update: Tasquinimod for the Treatment of Relapsed or Refractory Myeloma [Phase 1]
A University of Pennsylvania-sponsored Phase 1 trial of tasquinimod for relapsed or refractory multiple myeloma has been terminated.
-
CLINICAL_TRIALS other · 2025-10-07Clinical Trial Update: Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) [Phase 2, Phase 3]
Clinical trial update for Start Ig, a Phase 2/3 study investigating whether antibiotic therapy or intravenous immunoglobulin reduces infecti…
-
CLINICAL_TRIALS research · 2025-10-06Clinical Trial Update: Geriatric Assessment Guided Interventions to Accelerate Functional Recovery After CAR-T Therapy for Patients 60 Years and Older With B-cell Non-Hodgkin Lymphoma or Multiple Myeloma, GOCART Study [Phase 2]
Phase 2 clinical trial evaluating geriatric assessment-guided interventions to accelerate functional recovery after CAR-T therapy in patient…
-
EMA withdrawal · 2025-10-06EMA Application withdrawn: Aplidin (plitidepsin) — Pharma Mar S.A.
The EMA has withdrawn the marketing authorization application for Aplidin (plitidepsin) by Pharma Mar S.A. for the treatment of multiple mye…
-
CLINICAL_TRIALS research · 2025-10-03Clinical Trial Update: High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
The document announces a new clinical trial called HALO-SCT, assessing high-altitude observation in stem cell transplantation. It is current…
-
CLINICAL_TRIALS trial_result · 2025-10-03Clinical Trial Update: A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients
Clinical trial update on the bortezomib, lenalidomide, and dexamethasone regimen for newly diagnosed multiple myeloma, with the study status…